Last reviewed 2026-04-23 · How we verify

Glucocorticoids [Standard Dose]

University of Pennsylvania · Phase 3 active Small molecule

Glucocorticoids [Standard Dose] is a Glucocorticoid Small molecule drug developed by University of Pennsylvania. It is currently in Phase 3 development for Inflammatory and autoimmune disorders (specific indication in phase 3 trial unknown), Immunosuppression in transplantation or severe inflammatory conditions.

Glucocorticoids suppress immune and inflammatory responses by binding to glucocorticoid receptors and inhibiting pro-inflammatory cytokine production.

Glucocorticoids suppress immune and inflammatory responses by binding to glucocorticoid receptors and inhibiting pro-inflammatory cytokine production. Used for Inflammatory and autoimmune disorders (specific indication in phase 3 trial unknown), Immunosuppression in transplantation or severe inflammatory conditions.

Likelihood of approval

59.3% vs 58.3% industry baseline

If approved by FDA: likely 2028–2030

Steps remaining: NDA/BLA submission

Confidence: High

Why this estimate

Baseline phase 3 → approval rate +58.3pp
Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
Immunology slight uplift +1.0pp
Mature endpoint landscape (ACR, DAS28, PASI) makes immunology approvals slightly more predictable.

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2028–2030	—
EMA	EU	2029–2031	+0.7 yr
MHRA	GB	2029–2031	+0.7 yr
Health Canada	CA	2029–2032	+0.9 yr
TGA	AU	2029–2032	+1.2 yr
PMDA	JP	2029–2032	+1.5 yr
NMPA	CN	2030–2033	+2.3 yr
MFDS	KR	2029–2032	+1.4 yr
CDSCO	IN	2029–2033	+1.8 yr
ANVISA	BR	2030–2033	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	Glucocorticoids [Standard Dose]
Sponsor	University of Pennsylvania
Drug class	Glucocorticoid
Target	Glucocorticoid receptor (GR)
Modality	Small molecule
Therapeutic area	Immunology
Phase	Phase 3

Mechanism of action

Glucocorticoids are steroid hormones that bind intracellular glucocorticoid receptors, translocate to the nucleus, and modulate gene transcription to reduce production of inflammatory mediators (TNF-α, IL-1, IL-6) and suppress T-cell activation. They also promote apoptosis of lymphocytes and reduce vascular permeability, making them broad-spectrum anti-inflammatory and immunosuppressive agents.

Approved indications

Inflammatory and autoimmune disorders (specific indication in phase 3 trial unknown)
Immunosuppression in transplantation or severe inflammatory conditions

Common side effects

Hyperglycemia
Hypertension
Osteoporosis
Infection (opportunistic)
Insomnia
Mood changes
Weight gain

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Glucocorticoids [Standard Dose] CI brief — competitive landscape report
Glucocorticoids [Standard Dose] updates RSS · CI watch RSS
University of Pennsylvania portfolio CI

Frequently asked questions about Glucocorticoids [Standard Dose]

What is Glucocorticoids [Standard Dose]?

Glucocorticoids [Standard Dose] is a Glucocorticoid drug developed by University of Pennsylvania, indicated for Inflammatory and autoimmune disorders (specific indication in phase 3 trial unknown), Immunosuppression in transplantation or severe inflammatory conditions.

How does Glucocorticoids [Standard Dose] work?

Glucocorticoids suppress immune and inflammatory responses by binding to glucocorticoid receptors and inhibiting pro-inflammatory cytokine production.

What is Glucocorticoids [Standard Dose] used for?

Glucocorticoids [Standard Dose] is indicated for Inflammatory and autoimmune disorders (specific indication in phase 3 trial unknown), Immunosuppression in transplantation or severe inflammatory conditions.

Who makes Glucocorticoids [Standard Dose]?

Glucocorticoids [Standard Dose] is developed by University of Pennsylvania (see full University of Pennsylvania pipeline at /company/university-of-pennsylvania).

What drug class is Glucocorticoids [Standard Dose] in?

Glucocorticoids [Standard Dose] belongs to the Glucocorticoid class. See all Glucocorticoid drugs at /class/glucocorticoid.

What development phase is Glucocorticoids [Standard Dose] in?

Glucocorticoids [Standard Dose] is in Phase 3.

What are the side effects of Glucocorticoids [Standard Dose]?

Common side effects of Glucocorticoids [Standard Dose] include Hyperglycemia, Hypertension, Osteoporosis, Infection (opportunistic), Insomnia, Mood changes.

What does Glucocorticoids [Standard Dose] target?

Glucocorticoids [Standard Dose] targets Glucocorticoid receptor (GR) and is a Glucocorticoid.

Drug class: All Glucocorticoid drugs
Target: All drugs targeting Glucocorticoid receptor (GR)
Manufacturer: University of Pennsylvania — full pipeline
Therapeutic area: All drugs in Immunology
Indication: Drugs for Inflammatory and autoimmune disorders (specific indication in phase 3 trial unknown)
Indication: Drugs for Immunosuppression in transplantation or severe inflammatory conditions

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing